Follow-up US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Follow-up. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Follow-up US Medical PG Question 1: A 54-year-old man suffered an anterior wall myocardial infarction that was managed in the cath lab with emergent coronary stenting and revascularization. The patient states that his wife, adult children, and cousins may be disclosed information regarding his care and health information. The patient has been progressing well without any further complications since his initial catheterization. On hospital day #3, a woman stops you in the hall outside of the patient's room whom you recognize as the patient's cousin. She asks you about the patient's prognosis and how the patient is progressing after his heart attack. Which of the following is the most appropriate next step?
- A. Decline to comment per HIPAA patient confidentiality regulations
- B. Direct the woman to discuss these issues with the patient himself
- C. Ask the patient if it is acceptable to share information with this individual
- D. Discuss the patient's hospital course and expected prognosis with the woman
- E. Ask for identification confirming that the woman is truly the patient's cousin (Correct Answer)
Follow-up Explanation: ***Ask for identification confirming that the woman is truly the patient's cousin***
- While **HIPAA** emphasizes patient privacy, it also allows disclosure to family members if the patient has agreed to it or if disclosure is deemed in the patient's best interest.
- The patient explicitly stated that his cousins may be disclosed information; therefore, confirming the woman's identity as a cousin is the most **appropriate first step** to determine if she is one of the individuals he approved for information disclosure.
*Decline to comment per HIPAA patient confidentiality regulations*
- This is an overly broad and potentially **unnecessary response**, as the patient has already indicated that his cousins can receive information.
- **HIPAA allows for disclosure** to family members or others involved in the patient's care if the patient expresses a preference or does not object.
*Direct the woman to discuss these issues with the patient himself*
- This option **shifts the responsibility** of disclosure from the healthcare provider, who holds the medical information, to the patient.
- While the patient can certainly share his own information, the family may be seeking **professional medical updates** that the patient might not be fully equipped to provide.
*Ask the patient if it is acceptable to share information with this individual*
- Although obtaining direct patient consent is generally a good practice, the patient has already **verbally authorized family members**, including cousins, to receive information.
- The primary outstanding issue is confirming this specific individual's relationship to the patient, rather than re-asking for permission to share with cousins in general.
*Discuss the patient's hospital course and expected prognosis with the woman*
- This action would be **premature and a violation of HIPAA** if the woman cannot be confirmed as the patient's cousin.
- **Verification of identity** and relationship is crucial before disclosing any protected health information.
Follow-up US Medical PG Question 2: A 35-year-old woman is presenting for a general wellness checkup. She is generally healthy and has no complaints. The patient does not smoke, drinks 1 alcoholic drink per day, and exercises 1 day per week. She recently had silicone breast implants placed 1 month ago. Her family history is notable for a heart attack in her mother and father at the age of 71 and 55 respectively. Her father had colon cancer at the age of 70. Her temperature is 99.0°F (37.2°C), blood pressure is 121/81 mmHg, pulse is 77/min, respirations are 14/min, and oxygen saturation is 98% on room air. Physical exam is unremarkable. Which of the following is the most appropriate initial step in management?
- A. Alcohol cessation
- B. Colonoscopy at age 60
- C. Mammography at age 50
- D. Colonoscopy at age 40 (Correct Answer)
- E. Mammography now
Follow-up Explanation: ***Colonoscopy at age 40***
- This patient has a **first-degree relative (father) diagnosed with colorectal cancer at age 70**, which increases her risk compared to the average population.
- Current **USPSTF and ACS guidelines** recommend that individuals with a first-degree relative diagnosed with colorectal cancer at **age 60 or older** should begin screening at **age 40** (or 10 years before the age of diagnosis in the relative, whichever is earlier).
- Since her father was diagnosed at age 70, she should start screening at age 40 (which is 10 years earlier and also the recommended age for those with family history).
- At age 35, she does **not yet need** colonoscopy, but should plan for screening in 5 years.
*Colonoscopy now*
- This is **too early** based on current guidelines.
- Immediate colonoscopy at age 35 is not indicated in an asymptomatic patient whose father was diagnosed at age 70.
- Screening at age 40 provides adequate time for early detection while avoiding unnecessary early intervention.
*Colonoscopy at age 60*
- This is **too late** and ignores the increased risk from family history.
- Delaying screening until age 60 would miss the recommended earlier screening window for patients with first-degree relatives with CRC.
*Alcohol cessation*
- The patient drinks **1 alcoholic drink per day**, which is within recommended limits for women.
- While reducing alcohol consumption has general health benefits, this is not the most urgent preventive measure given her family history of colon cancer.
*Mammography now*
- Screening mammography typically begins at **age 40-50** for average-risk women.
- At age 35 with no specific high-risk factors (no BRCA mutation, no strong early-onset breast cancer family history), mammography is not indicated now.
*Mammography at age 50*
- While this may be appropriate for breast cancer screening depending on guidelines followed, it is **not the priority** given her significant family history of colorectal cancer requiring earlier intervention.
Follow-up US Medical PG Question 3: An otherwise healthy 67-year-old woman comes to your clinic after being admitted to the hospital for 2 weeks after breaking her hip. She has not regularly seen a physician for the past several years because she has been working hard at her long-time job as a schoolteacher. You wonder if she has not been taking adequate preventative measures to prevent osteoporosis and order the appropriate labs. Although she is recovering from surgery well, she is visibly upset because she is worried that her hospital bill will bankrupt her. Which of the following best describes her Medicare coverage?
- A. Medicare Part C will cover the majority of drug costs during her inpatient treatment.
- B. Medicare Part A will cover the majority of her hospital fees, including inpatient drugs and lab tests. (Correct Answer)
- C. Medicare is unlikely to cover the cost of her admission because she has not been paying her premium.
- D. Medicare Part B will cover the majority of her hospital fees, including inpatient drugs and lab tests.
- E. Medicare Part D will cover the cost of drugs during her inpatient treatment.
Follow-up Explanation: ***Medicare Part A will cover the majority of her hospital fees, including inpatient drugs and lab tests.***
* **Medicare Part A** is hospital insurance and covers **inpatient hospital stays**, skilled nursing facility care, hospice care, and some home health care. This includes services received during an inpatient stay such as drugs, lab tests, and surgery.
* Given her 2-week hospital stay for a broken hip, which resulted in surgery and ongoing recovery, Part A would be the primary payer for the majority of these costs.
*Medicare Part C will cover the majority of drug costs during her inpatient treatment.*
* **Medicare Part C**, also known as **Medicare Advantage**, is an alternative to original Medicare provided by private companies, often including Part A, B, and D benefits.
* While Part C plans can cover drug costs, **inpatient drugs** administered during a hospital stay are typically covered under **Part A**, not a separate drug plan, if the patient is using original Medicare. If she has a Part C plan, it would integrate these benefits.
*Medicare is unlikely to cover the cost of her admission because she has not been paying her premium.*
* Medicare Part A is generally **premium-free** for most individuals who have paid Medicare taxes through their employment for at least 10 years (or 40 quarters).
* Given her long career as a schoolteacher, it is highly likely she would qualify for premium-free Part A, making this statement incorrect.
*Medicare Part B will cover the majority of her hospital fees, including inpatient drugs and lab tests.*
* **Medicare Part B** is medical insurance and covers **doctor's services**, outpatient care, medical supplies, and preventive services.
* While it covers some outpatient lab tests and physician services received during an inpatient stay, it does not cover the primary costs of **inpatient hospital fees** or drugs administered during an inpatient stay, which fall under Part A.
*Medicare Part D will cover the cost of drugs during her inpatient treatment.*
* **Medicare Part D** is prescription drug coverage provided by private companies and covers **outpatient prescription drugs**.
* Medications administered to an **inpatient** during a hospital stay (i.e., when she is admitted) are typically covered under **Medicare Part A**, not Part D.
Follow-up US Medical PG Question 4: A 28-year-old woman dies shortly after receiving a blood transfusion. Autopsy reveals widespread intravascular hemolysis and acute renal failure. Investigation reveals that she received type A blood, but her medical record indicates she was type O. In a malpractice lawsuit, which of the following elements must be proven?
- A. Duty, breach, causation, and damages (Correct Answer)
- B. Only duty and breach
- C. Only breach and causation
- D. Duty, breach, and damages
Follow-up Explanation: ***Duty, breach, causation, and damages***
- In a medical malpractice lawsuit, all four elements—**duty, breach, causation, and damages**—must be proven for a successful claim.
- The healthcare provider had a **duty** to provide competent care, they **breached** that duty by administering the wrong blood type, this breach **caused** the patient's death and renal failure, and these injuries constitute **damages**.
*Only duty and breach*
- While **duty** and **breach** are necessary components, proving only these two is insufficient for a malpractice claim.
- It must also be demonstrated that the breach directly led to the patient's harm and resulted in legally recognized damages.
*Only breach and causation*
- This option omits the crucial elements of professional **duty** owed to the patient and the resulting **damages**.
- A claim cannot succeed without establishing that a duty existed and that quantifiable harm occurred.
*Duty, breach, and damages*
- This option misses the critical element of **causation**, which links the provider's breach of duty to the patient's injuries.
- Without proving that the breach *caused* the damages, even if a duty was owed and breached, and damages occurred, the claim would fail.
Follow-up US Medical PG Question 5: An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?
- A. 20
- B. 73
- C. 10 (Correct Answer)
- D. 50
- E. 100
Follow-up Explanation: ***10***
- The **number needed to treat (NNT)** is calculated by first finding the **absolute risk reduction (ARR)**.
- **ARR** = Risk in control group - Risk in treatment group = 25% - 15% = **10%** (or 0.10).
- **NNT = 1 / ARR** = 1 / 0.10 = **10 patients**.
- This means that **10 patients must be treated with Noxbinle to prevent one death from HCC** over 5 years.
*20*
- This would result from an ARR of 5% (1/0.05 = 20), which is not supported by the data.
- May arise from miscalculating the risk difference or incorrectly halving the actual ARR.
*73*
- This value does not correspond to any standard calculation of NNT from the given mortality rates.
- May result from confusion with other epidemiological measures or calculation error.
*50*
- This would correspond to an ARR of 2% (1/0.02 = 50), which significantly underestimates the actual risk reduction.
- Could result from incorrectly calculating the difference as a proportion rather than absolute percentage points.
*100*
- This would correspond to an ARR of 1% (1/0.01 = 100), grossly underestimating the treatment benefit.
- May result from confusing ARR with relative risk reduction or other calculation errors.
More Follow-up US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
